Disease characteristic
MONDO:0021125An attribute of a disease.
Also known as: disease qualifier, modifier, qualifier
18 clinical trials for this condition and its sub-types, 2 tagged with Disease characteristic itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Disease characteristic
-
Infectious disease characteristic 0 trials · 8 incl. sub-types
2 sub-types
- Opportunistic infectious 8 trials
- Primary infectious 0 trials
-
Hereditary vs non-hereditary etiology 0 trials · 4 incl. sub-types
2 sub-types
- Inherited 4 trials
- Non-genetic 0 trials
-
Tumor grading characteristic 0 trials · 3 incl. sub-types
1 sub-type
- General tumor grading characteristic 0 trials · 3 incl. sub-types Sub-types →
-
Congenital or acquired 1 trial · 2 incl. sub-types
2 sub-types
- Congenital 1 trial
- Acquired 0 trials
-
2 sub-types
- Classic presentation 0 trials
- Non-classic presentation 0 trials
-
Iatrogenic or non-iatrogenic 0 trials
2 sub-types
- Iatrogenic 0 trials
- Non-iatrogenic 0 trials
-
Idiopathic vs non-idiopathic 0 trials
2 sub-types
- Idiopathic 0 trials
- Non-idiopathic 0 trials
-
Locational disease characteristic 0 trials
2 sub-types
- Disseminated 0 trials
- Restricted to specific location 0 trials
-
Mosaic vs complete 0 trials
-
Rare or common 0 trials
-
Syndromic or isolated 0 trials
2 sub-types
- Has a syndromic presentation 0 trials
- Has an isolated presentation 0 trials
Most studied deeper sub-types
-
Drug could slash surgeries for rare airway disease
Disease control OngoingThis phase II trial tests whether bevacizumab, a drug that blocks blood vessel growth, can lengthen the time between surgeries for adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants receive 11 doses of t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New Virus-Based therapy targets bladder cancer after BCG fails
Disease control CancelledThis study tested a treatment called CG0070, a virus designed to attack cancer cells, in people with high-grade non-muscle invasive bladder cancer. Participants had already tried standard therapy (BCG) without success and chose not to have their bladder removed. The goal was to s…
Phase 2 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Mystery infections in healthy people: scientists investigate
Knowledge-focused OngoingThis study looks at HIV-negative people who get opportunistic infections—illnesses that usually only affect those with weak immune systems. Researchers want to find out if these patients have unusual antibodies that block a key immune signal. Up to 224 adults in Thailand and Taiw…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC